Zhejiang Shouxiangu Pharmaceutical Full Year 2024 Earnings: Misses Expectations

Simply Wall St

March 31, 2025

Zhejiang Shouxiangu Pharmaceutical (SHSE:603896) Full Year 2024 Results

Key Financial Results

Revenue: CN¥699.1m (down 11% from FY 2023).
Net income: CN¥153.0m (down 40% from FY 2023).
Profit margin: 22% (down from 32% in FY 2023). The decrease in margin was primarily driven by lower revenue.
EPS: CN¥0.93 (down from CN¥1.30 in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-growth — SHSE:603896 Earnings and Revenue Growth March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zhejiang Shouxiangu Pharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 35%.

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Personal Products industry in China.

Performance of the Chinese Personal Products industry.

The company's shares are down 2.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Zhejiang Shouxiangu Pharmaceutical that you need to take into consideration.

If you're looking to trade Zhejiang Shouxiangu Pharmaceutical, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Zhejiang Shouxiangu Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.